ZELAN BHD
AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING

CONCERN AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN UNQUALIFIED OPINION WITH MATERIAL UNCERTAINTY RELATED TO GOING CONCERN IN ZELANBERHAD AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019

15/07/2020

Pdz Anzo same from 5c up to above 24c .end show... now drop below 20c retracing...

Pdz Anzo same from 5c up to above 24c .end show now drop below 20c retracing...

pdz-wb conversion 10c ,have not move up... pdz end show in retracing....

Pursuant to Paragraph 9.11 of the Main Market Listing Requirement (“LR”) of Bursa Securities, the Board of Directors of PDZ, after having made due inquiries with all the Directors, Major Shareholders and such other relevant persons, wishes to inform that to the best of their knowledge, the following:-

1) There are no corporate development relating to the Group’s business and affairs that has not been previously announced that may account for the trading activity including those in the stage of negotiation/discussion;

2) The Directors are not aware of any rumour or report concerning the business and affairs of the Group that may account for the trading activity;

3) The Directors are not aware of any other possible explanation to account for the trading activity; and

4) The Company is in compliance with the Bursa Securities LR, in particular Paragraph 9.03 of the Bursa securities LR on immediate disclosure obligations.

This announcement is dated 10 July 2020.

Jul 8, 2020 when i tell everybody but nobody believe me....Now they believe liao...

Posted by kenie > Jul 8, 2020 10:41 AM
ANZO
cash flow 0.61 mil
debt -
current liabilities 11.86 mil


Posted by kenie > Jul 8, 2020 10:44 AM
Anzo cash sixty thousand.. .how to buy 55 mil glove company ...Anzo same as Mqtech talk talk kok



Posted by kenie > Jul 8, 2020 10:44 AM
Anzo cash sixty thousand no enough pay worker salary la.. . YES gloveking619 switch your all cash to anzo help pay salary current liabilities

Notice of Person Ceasing
08/07/2020 CSTME RESOURCES SDN. BHD Disposed 52,200,000

07/07/2020 CSTME RESOURCES SDN. BHD Disposed 62,920,000

8 Jul 2020 PDZ PELABURAN MARA BERHAD 50,618,954 units Disposed

UMA no more show lo..

ARB BERHAD
Additional Listing Announcement /Subdivision of Shares

Details of corporate proposal
Details of corporate proposal : Conversion of Irredeemable Convertible Preference Shares to Ordinary Shares
No. of shares issued under this corporate proposal : 35,968,000
Issue price per share ($$) : 0.20
Listing Date : 13/07/2020

Bursa Malaysia Securities Berhad has on 10 July 2020 issued an UMA query on the sharp rise in the price and volume of PDZ shares recently.

Anzo cash sixty thousand no enough pay worker salary la.. . YES gloveking619 switch your all cash to anzo help pay salary current liabilities

Anzo cash sixty thousand.. .how to buy 55 mil glove company ...Anzo same as Mqtech talk talk kok

ANZO
cash flow 0.61 mil
debt -
current liabilities 11.86 mil

knm up and down is lee swee eng goreng...No lee KNM no show lo...

Insider trading Lee Swee Eng

On 29 April 2020, a civil action was initiated against Lee Swee Eng for an alleged breach of section 188(2) of the Capital Markets and Services Act 2007 (CMSA) in respect of the disposal of KNM Group Berhad shares by Lee Swee Eng. The SC sought, among others, the following:

A declaration that Lee Swee Eng has contravened section 188(2) of the CMSA;
Payment of the sum of RM11,003,574.00 which is equivalent to three (3) times the amount of RM3,667,858.00 being the difference between the price at which the said shares were disposed and the price at which the said shares would have been likely to have been disposed at the time of the disposal, if the Inside Information had been made generally available;
A civil penalty of RM1,000,000.00;
An order that Chang Kee Soon be removed of directorship and management positions in any public listed companies in Malaysia;
An order that Lee Swee Eng be barred from being a chief executive or director from being involved in the management, directly or indirectly of any public listed company in Malaysia for a period of 5 years from the date of judgment;
An order that Lee Swee Eng be restrained from trading in any securities on Bursa Malaysia for a period of 5 years from the date of judgment.
Interest and Costs.

AIRASIA GROUP BERHAD - ISSUANCE OF UNQUALIFIED AUDIT OPINION WITH EMPHASIS OF MATTER ON MATERIAL UNCERTAINTY RELATING TO GOING CONCERN
AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN

AIRASIA GROUP BERHAD - ISSUANCE OF UNQUALIFIED AUDIT OPINION WITH EMPHASIS OF MATTER ON MATERIAL UNCERTAINTY RELATING TO GOING CONCERN
AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN

AIRASIA GROUP BERHAD - ISSUANCE OF UNQUALIFIED AUDIT OPINION WITH EMPHASIS OF MATTER ON MATERIAL UNCERTAINTY RELATING TO GOING CONCERN
AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN

AIRASIA GROUP BERHAD - ISSUANCE OF UNQUALIFIED AUDIT OPINION WITH EMPHASIS OF MATTER ON MATERIAL UNCERTAINTY RELATING TO GOING CONCERN
AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN

SUBDIVISION / CONSOLIDATION OF SHARES (CHAPTER 13 OF LISTING REQUIREMENTS) EDUSPEC HOLDINGS BERHAD PROPOSED SHARE CONSOLIDATION

Share Consolidation of every 2 existing Eduspec Shares held by the registered holders into 1 shares

2020 will losses 3.96 billion same fate as MAS will banruptcy

Anzo sixty one thousand Win... trade... in ...World

ANZO
cash flow 0.61 mil
debt -
current liabilities 11.86 mil

mqtech thirty four thousand buy sembelit

MQtech
cash flow 0.34 mil
short term debt 0.01 mil
current liabilities 3.76 mil

Anzo cash sixty thousand no enough pay worker salary la...how to buy 55 mil glove company ...Anzo same as Mqtech tal talk kok

ANZO
cash flow 0.61 mil
debt -
current liabilities 11.86 mil

LEE SWEE ENG Disposed 50,000,000

trive sleeping reason...

cash flow 2.08 mil
debt 51.60 mil
current liabilities 28.31 mil

oilwaterman armarda sail slower because ..https://klse.i3investor.com/blogs/tombthieve/2020-04-27-story-h1506137503-BEWARE_INVESTING_OIL_AND_GAS_COMPANY.jsp

yingzhe17 knm problem reason tomb say...
https://klse.i3investor.com/blogs/tombthieve/2020-04-27-story-h1506137503-BEWARE_INVESTING_OIL_AND_GAS_COMPANY.jsp

kasrim sapnrg no up reason tomb say...
https://klse.i3investor.com/blogs/tombthieve/2020-04-27-story-h1506137503-BEWARE_INVESTING_OIL_AND_GAS_COMPANY.jsp

https://klse.i3investor.com/blogs/tombthieve/2020-04-27-story-h1506137503-BEWARE_INVESTING_OIL_AND_GAS_COMPANY.jsp

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The Indian Council of Medical Research (ICMR) has announced that it is planning to fast track the human clinical trials of coronavirus vaccine which is being developed in partnership with Bharat Biotech International Limited (BBIL).
Also read: Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials
ICMR Director General Balram Bhargava, in a letter to the heads of the selected institutions, informed them that it has partnered with Hyderabad-based Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
"The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine," he wrote.
The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.
The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
The institutes selected for the clinical trial are Bhubaneswar's IMS and SUM Hospital, and other institutes are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

IKHMAS AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING

22-Jun-2020. everybody buy at 7 cent boss MQtech WANG YONG KANG selling...

Notice of ceasing to be substantial holder - MR WANG YONG KANG Disposed 40,000,000 on 22-Jun-2020.

22 May 2020 ECO WORLD DEVELOPMENT HOLDINGS SDN. BHD. Disposed 30,000,000

BOSS LIEW TIAN XIONG (10,000,000 units Disposed)
22 May 2020

4 May 2020 ECOWLD EMPLOYEES PROVIDENT FUND BOARD (192,800 units Disposed)

30 Apr 2020 ECOWLD EMPLOYEES PROVIDENT FUND BOARD (1,005,000 units Disposed)

29 Apr 2020 ECOWLD EMPLOYEES PROVIDENT FUND BOARD (3,000,000 units Disposed)

23 Apr 2020 ECOWLD EMPLOYEES PROVIDENT FUND BOARD (8,650,500 units Disposed)

22 Apr 2020 ECOWLD EMPLOYEES PROVIDENT FUND BOARD (9,100,000 units Disposed)

EPF all the way disposal ECO

20% down payment need 150k ,bank tightening lending ,property sales drop...
ecoworld financial rolling tightening problem ...

ecoworld
cash flow 269 mil
short term debt 1.91 bil
long term debt 1.695 bil
current liabilities 4.04 bil